Ansuvimab

Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola

Retrieved on: 
Thursday, July 7, 2022
Department, United States Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, FDA, Patient, Assistant, LinkedIn, Life, CEO, Biomedical Advanced Research and Development Authority, Emergent BioSolutions, GLOBE, Infection, COVID-19, Sale, Public health, Development, Merck, Food, Contract, Therapy, Emergent, Partnership, Private Securities Litigation Reform Act, NYSE, SEC, Risk, Solution, Instagram, Vaccine, Twitter, Ansuvimab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EBS, Pharmaceutical industry, Bookkeeping, Ebola

and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (Ridgeback Bio), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga (Ansuvimab-zykl).

Key Points: 
  • and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (Ridgeback Bio), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga (Ansuvimab-zykl).
  • Ebanga was approved by the U.S. Food and Drug Administration (FDA) in December 2020 for the treatment of Ebola.
  • Ebanga is a monoclonal antibody with antiviral activity provided through a single injection and was developed for the treatment of Ebola by Ridgeback Bio under license from theNational Institute of Allergy and Infectious Diseases.
  • In line with Ridgeback Bios mission for equitable global access, all Ridgeback Bio services and treatment for Ebola patients in Africa are delivered free of charge.

Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo

Retrieved on: 
Wednesday, October 20, 2021
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Biomedical Advanced Research and Development Authority, Institut National pour la Recherche Biomedicale, Clinical trial, Severe acute respiratory syndrome coronavirus 2, Protalix BioTherapeutics, Democratic republic, Global Affairs Canada, NIAID, View, Death, Assistant, COVID-19, Institut national de recherche et de sécurité, Pharmacist, Antibody, PCR, VRC, Diagnosis, Merck, Contract, Collection, Senior, Data collection, Office of the Assistant Secretary for Preparedness and Response, Infection, Department, LP, United States Department of Health and Human Services, Ministry, CEO, VIR, Ansuvimab, EVD, Disease, Patient, Survival, DRC, Biodefense, Merck & Co., Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ministry of Health and Social Welfare, Liberia, Vaccine, Pharmaceutical industry

Ridgeback Biotherapeutics (Ridgeback Bio), a biotechnology company experienced in antiviral drug development including medicines to treat SARS-Cov-2 and Ebola, announces deployment of the Ridgeback Ebola Rapid Response team to the Democratic Republic of the Congo (DRC).

Key Points: 
  • Ridgeback Biotherapeutics (Ridgeback Bio), a biotechnology company experienced in antiviral drug development including medicines to treat SARS-Cov-2 and Ebola, announces deployment of the Ridgeback Ebola Rapid Response team to the Democratic Republic of the Congo (DRC).
  • Ridgeback Bio is supporting a team of clinicians and pharmacists specialized in the treatment of Ebola Virus Disease (EVD) patients.
  • In order to achieve this, we have established the Ridgeback Ebola Rapid Response team which will work with our partners at the Institut National de Recherche in the Democratic Republic of the Congo.
  • Ridgeback Biotherapeutics markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.